Lederfolat Anwendung Bei Erwachsenen Und Kindern

Calcium folinate, the active ingredient in Lederfolat Anwendung Bei Erwachsenen Und Kindern, is a folate analog presented as an oral formulation for oral use. It is employed to counteract folate deficiency, mitigate methotrexate toxicity, and serve as an adjunct in cancer chemotherapy for both adults and children.

GNH USA supplies Lederfolat Anwendung Bei Erwachsenen Und Kindern as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for import.

Lederfolat (calcium folinate) is used in clinical situations that require restoration of folate‑dependent pathways. - Methotrexate toxicity: provides rapid rescue from high‑dose methotrexate‑induced folate blockade. - Folate deficiency: restores normal folate levels in patients with inadequate dietary intake or malabsorption. - Cancer chemotherapy adjunct: enhances efficacy of antifolate agents by supplying reduced folate for DNA synthesis.

Calcium folinate may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Rash - Headache

Serious or Rare Side Effects: - Anaphylaxis (severe allergic reaction) - Neutropenia - Hepatic dysfunction - Renal impairment

When prescribing calcium folinate, several safety considerations should be observed. - Renal function: assess baseline renal function and monitor during therapy. - Hepatic function: evaluate liver enzymes before initiation and periodically. - Folate status: confirm folate deficiency or need for rescue before use. - Hypersensitivity: avoid in patients with known allergy to calcium folinate or other folate analogs. - Pregnancy: use only if potential benefit justifies potential risk; consult obstetric specialist. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Calcium folinate can modify the effects of several concomitant medicines.

Major Interactions (Avoid): - Methotrexate: concurrent use may reduce methotrexate toxicity but requires careful dosing. - Antifolate agents (e.g., pemetrexed): may antagonize therapeutic effect. - Trimethoprim‑sulfamethoxazole: can increase risk of hematologic toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase renal risk when combined with calcium folinate. - Proton pump inhibitors: may affect folate absorption and require monitoring.